Literature DB >> 24656562

Efficacy and safety of intrauterine insemination in patients with moderate-to-severe endometriosis.

Lisette E E van der Houwen1, Anneke M F Schreurs2, Roel Schats2, Martijn W Heymans3, Cornelis B Lambalk2, Peter G A Hompes2, Velja Mijatovic2.   

Abstract

Performing intrauterine insemination (IUI) in moderate-to-severe endometriosis patients is not implemented in international guidelines, as only limited data exist on treatment efficacy and safety. This retrospective study examined the efficacy and safety of two IUI treatment strategies performed between January 2007 and July 2012 in moderate-to-severe endometriosis patients. Eight (40.0%) versus seven (15.6%) ongoing pregnancies were accomplished in patients undergoing IUI with ovarian stimulation (n=20, 61 cycles) versus IUI without ovarian stimulation in the first three cycles followed by IUI with ovarian stimulation (IUI with natural/ovarian stimulation; n=45, 184 cycles). Preceding long-term pituitary down-regulation tended to result in a higher ongoing pregnancy rate (adjusted HR 1.8) and a higher chance of endometriosis recurrence (adjusted HR 2.3). Eight (40.0%) versus 16 (35.6%) recurrences of endometriosis complaints were reported in patients receiving IUI with ovarian stimulation versus IUI with natural/ovarian stimulation. IUI might be a valuable treatment in moderate-to-severe endometriosis patients and IUI with ovarian stimulation should be offered over IUI with natural/ovarian stimulation. Preceding long-term pituitary down-regulation might positively influence the ongoing pregnancy rate and can be considered. Whether this treatment strategy can be structurally offered prior to IVF must be investigated in a randomized controlled trial.
Copyright © 2014 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GnRH agonist; complication; endometriosis; intrauterine insemination; ongoing pregnancy rate; recurrence

Mesh:

Year:  2014        PMID: 24656562     DOI: 10.1016/j.rbmo.2014.01.005

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  6 in total

1.  Factors associated with a poor prognosis for the IVF-ICSI live birth rate in women with rAFS stage III and IV endometriosis.

Authors:  Pauline Roux; Jeanne Perrin; Julien Mancini; Aubert Agostini; Léon Boubli; Blandine Courbiere
Journal:  J Assist Reprod Genet       Date:  2017-05-18       Impact factor: 3.412

Review 2.  Endometriosis and Infertility: A Long-Life Approach to Preserve Reproductive Integrity.

Authors:  Maria Elisabetta Coccia; Luca Nardone; Francesca Rizzello
Journal:  Int J Environ Res Public Health       Date:  2022-05-19       Impact factor: 4.614

3.  Risk factors for the development of tubo-ovarian abscesses in women with ovarian endometriosis: a retrospective matched case-control study.

Authors:  Yang Gao; Pengpeng Qu; Yang Zhou; Wei Ding
Journal:  BMC Womens Health       Date:  2021-01-30       Impact factor: 2.809

4.  Efficacy of intrauterine insemination in women with endometrioma-associated subfertility: analysis using propensity score matching.

Authors:  He Cai; Jinlin Xie; Juanzi Shi; Hui Wang
Journal:  BMC Pregnancy Childbirth       Date:  2022-01-04       Impact factor: 3.007

5.  Pregnancy Rate after Controlled Ovarian Hyperstimulation and Intrauterine Insemination for the Treatment of Endometriosis following Surgery.

Authors:  Attila Keresztúri; Zoltan Kozinszky; József Daru; Norbert Pásztor; János Sikovanyecz; János Zádori; Virág Márton; Sándor Koloszár; János Szöllősi; Gábor Németh
Journal:  Biomed Res Int       Date:  2015-07-12       Impact factor: 3.411

6.  Decreased Level of Neurotrophic Factor Neuritin 1 in Women with Ovarian Endometriosis after Receiving Gonadotropin-Releasing Hormone Agonist Treatment.

Authors:  Endah Rahmawati; Wei-Chung Vivian Yang; Yen-Ping Lei; Pawan Kumar Maurya; Huei-Wen Chen; Chii-Ruey Tzeng
Journal:  Int J Mol Sci       Date:  2019-09-05       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.